drugset / Trial / NCT02516046

18F-AV-1451 Autopsy Study

NCT02516046

Phase 3 Completed 156 enrolled Avid Radiopharmaceuticals
NaSingle-groupOpen-labelDiagnostic

Summary

This study is designed to test the relationship between ante-mortem flortaucipir Positron Emission Tomography (PET) imaging and tau neurofibrillary pathology associated with Alzheimer's disease (AD), as measured at autopsy.

Timeline

Start
2015-09
Primary completion
2018-06-13
Completion
2018-07-15

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Flortaucipir Diagnostic / imaging agent 370 mbq Intravenous

Indications